{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:55:50Z","timestamp":1778856950417,"version":"3.51.4"},"reference-count":54,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1016\/j.beha.2006.06.008","type":"journal-article","created":{"date-parts":[[2006,9,23]],"date-time":"2006-09-23T07:29:43Z","timestamp":1158996583000},"page":"701-713","source":"Crossref","is-referenced-by-count":27,"title":["Novel antibody-based therapy for acute lymphoblastic leukaemia"],"prefix":"10.1016","volume":"19","author":[{"given":"Nicola","family":"G\u00f6kbuget","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dieter","family":"Hoelzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2006.06.008_bib1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1040-8428(00)00097-4","article-title":"Recent approaches in acute lymphoblastic leukemia in adults","volume":"36","author":"Hoelzer","year":"2000","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10.1016\/j.beha.2006.06.008_bib2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2006.06.008_bib3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/shem.2002.36923","article-title":"Monoclonal antibody therapies in leukemias","volume":"39","author":"Tallman","year":"2002","journal-title":"Seminars in Hematology"},{"key":"10.1016\/j.beha.2006.06.008_bib4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00277-003-0752-8","article-title":"Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects","volume":"83","author":"G\u00f6kbuget","year":"2003","journal-title":"Annals of Hematology"},{"key":"10.1016\/j.beha.2006.06.008_bib5","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.524.524","article-title":"Overexpression of Her-2\/neu is observed in one third of adult B-ALL patients and is associated with chemoresistance in these patients","volume":"104","author":"Chevallier","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.06.008_bib6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30156","article-title":"Rituximab: mechanism of action and resistance","volume":"29","author":"Maloney","year":"2002","journal-title":"Seminars in Oncology"},{"key":"10.1016\/j.beha.2006.06.008_bib7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2006.06.008_bib8","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/sj.bjc.6601187","article-title":"Clinical use of rituximab in haematological malignancies","volume":"89","author":"Avivi","year":"2003","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.beha.2006.06.008_bib9","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/mpo.1335","article-title":"Rituximab with interleukin-2 after autologous bone marrow transplantation for acute lymphocytic leukemia in second remission","volume":"38","author":"Ozsahin","year":"2002","journal-title":"Medical and Pediatric Oncology"},{"key":"10.1016\/j.beha.2006.06.008_bib10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/sj.bmt.1702706","article-title":"Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemia","volume":"27","author":"Jandula","year":"2001","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.beha.2006.06.008_bib11","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1365-2141.2004.04925.x","article-title":"Rituximab in three children with relapsed\/refractory B-cell acute lymphoblastic leukaemia\/Burkitt non-Hodgkin's lymphoma","volume":"125","author":"De Vries","year":"2004","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2006.06.008_bib12","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00043426-200304000-00013","article-title":"Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation","volume":"25","author":"Corbacioglu","year":"2003","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"key":"10.1016\/j.beha.2006.06.008_bib13","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/blood.V87.2.495.bloodjournal872495","article-title":"Improved outcome in adult B-cell acute lymphoblastic leukemia","volume":"87","author":"Hoelzer","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.06.008_bib14","first-page":"159a","article-title":"Successful treatment of Burkitt's NHL and other high-grade NHL according to a protocol for mature B-ALL","volume":"100","author":"Hoelzer","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.06.008_bib15","article-title":"Short intensive chemotherapy with rituximab seems successful in Burkitt NHL, mature B-ALL and other high-grade B-NHL","volume":"102","author":"Hoelzer","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.06.008_bib16","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.2732.2732","article-title":"Subtype adjusted therapy improves outcome of elderly patients with acute lymphoblastic leukemia","volume":"104","author":"Hoelzer","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.06.008_bib17","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.149.149","article-title":"Chemo-immunotherapy with hyper-CVAD plus ritixumab for adult Burkitt's and Burkitt's type lymphoma (BL) or acute lymphoblastic leukemia (B-ALL)","volume":"106","author":"Thomas","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.06.008_bib18","first-page":"#3104","article-title":"Results of a shortened, dose reduced treatment protocol in elderly patients with acute lymphoblastic leukemia (ALL) [abstract]","volume":"96","author":"G\u00f6kbuget","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.06.008_bib19","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.1831.1831","article-title":"Update of the modified hyper-CVAD regimen with or without rituximab in newly diagnosed adult acute lymphocytic leukemia (ALL)","volume":"106","author":"Thomas","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.06.008_bib20","first-page":"#3115","article-title":"Upfront treatment with B43 PAP immunotoxin in newly diagnosed children with higher risk ALL - Children's Cancer Group 1961","volume":"96","author":"Seibel","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.06.008_bib21","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/cncr.11219","article-title":"Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine","volume":"97","author":"Szatrowski","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2006.06.008_bib22","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/00002371-200111000-00008","article-title":"Phase I trial of anti-B4-blocked ricin in pediatric patients with leukemia and lymphoma","volume":"24","author":"Dinndorf","year":"2001","journal-title":"Journal of Immunotherapy"},{"key":"10.1016\/j.beha.2006.06.008_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/10428199909093730","article-title":"Poor treatment outcome of Philadelphia chromosome-positive pediatric acute lymphoblastic leukemia despite intensive chemotherapy","volume":"33","author":"Uckun","year":"1999","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.beha.2006.06.008_bib24","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/sj.leu.2401779","article-title":"Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro","volume":"14","author":"Herrera","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2006.06.008_bib25","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/sj.leu.2402790","article-title":"Treatment of SCID\/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins","volume":"17","author":"Herrera","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2006.06.008_bib26","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/blood-2003-07-2466","article-title":"Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies","volume":"103","author":"Dijoseph","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.06.008_bib27","first-page":"3024","article-title":"BL22, an anti-CD22 recombinant immunotoxin, is active in vitro and in vivo against B-cell precursor acute lymlphoblastic leukemia (BCP-ALL) cells from pediatric patients","volume":"100","author":"Lew","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.06.008_bib28","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.872.872","article-title":"Acute lymphoblastic leukemia cells carrying the t(12;21) translocation are highly sensitive to alemtuzumab mediated cell lysis","volume":"106","author":"Golay","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.06.008_bib29","first-page":"#1191","article-title":"Treatment of acute lymphoblastic leukemia (ALL) with Campath-1H: initial observations","volume":"84","author":"Kolitz","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.06.008_bib30","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/10428190310001603948","article-title":"Anti-leukemic and anti-GVHD effects of Campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation","volume":"45","author":"Piccaluga","year":"2004","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.beha.2006.06.008_bib31","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/sj.leu.2403422","article-title":"Remission of adult acute lymphocytic leukaemia with alemtuzumab","volume":"18","author":"Laporte","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2006.06.008_bib32","first-page":"1397a","article-title":"A broad exploratory trial of Campath-1H in the treatment of acute leukemias","volume":"96","author":"Faderl","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.06.008_bib33","article-title":"Incorporation of alemtuzumab into front-line therapy of adult acute lymphoblastic leukemia (ALL) is feasible: a phase I\/II study from the Cancer and Leukemia Group B (CALGB 10102)","volume":"106","author":"Stock","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.06.008_bib34","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/sj.bmt.1703737","article-title":"Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation","volume":"30","author":"Massenkeil","year":"2002","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.beha.2006.06.008_bib35","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood.V82.6.1701.1701","article-title":"The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia","volume":"82","author":"Waldmann","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.06.008_bib36","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2004-05-1709","article-title":"Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody","volume":"105","author":"Zhang","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.06.008_bib37","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2141.2005.05872.x","article-title":"The role of gemtuzumab ozogamicin in acute leukaemia therapy","volume":"132","author":"Tsimberidou","year":"2006","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2006.06.008_bib38","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/sj.leu.2403737","article-title":"Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy","volume":"19","author":"Mejstrikova","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2006.06.008_bib39","article-title":"Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo","author":"Golay","year":"2005","journal-title":"The Hematology Journal"},{"key":"10.1016\/j.beha.2006.06.008_bib40","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/sj.leu.2402749","article-title":"Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin","volume":"17","author":"Zwaan","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2006.06.008_bib41","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1046\/j.1365-2141.2003.04485.x","article-title":"Successful use of gemtuzumab ozogamicin in a child with relapsed CD33-positive acute lymphoblastic leukaemia","volume":"122","author":"Cotter","year":"2003","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2006.06.008_bib42","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/sj.leu.2403134","article-title":"Molecular remission induced by gemtuzumab ozogamicin associated with donor lymphocyte infusions in t(4;11) acute lymphoblastic leukemia relapsed after transplantation","volume":"17","author":"Balduzzi","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2006.06.008_bib43","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.leukres.2004.08.011","article-title":"New anti-T cell immunotoxins for the clinic","volume":"29","author":"Frankel","year":"2005","journal-title":"Leukemia Research"},{"key":"10.1016\/j.beha.2006.06.008_bib44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0022-1759(96)00127-5","article-title":"Laboratory preparation of a deglycosylated ricin toxin a chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies","volume":"197","author":"Vallera","year":"1996","journal-title":"Journal of Immunological Methods"},{"key":"10.1016\/j.beha.2006.06.008_bib45","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/10428199709051778","article-title":"Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin","volume":"26","author":"Frankel","year":"1997","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.beha.2006.06.008_bib46","first-page":"881","article-title":"In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin","volume":"3","author":"Waurzyniak","year":"1997","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1016\/j.beha.2006.06.008_bib47","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1182\/blood-2002-11-3601","article-title":"Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507","volume":"102","author":"Zhang","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.06.008_bib48","first-page":"390","article-title":"Therapy with OKT3 monoclonal antibody in refractory T cell acute lymphoblastic leukemia induces interleukin-2 responsiveness","volume":"9","author":"Gramatzki","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2006.06.008_bib49","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1182\/blood.V99.8.2712","article-title":"A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease","volume":"99","author":"Carpenter","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.06.008_bib50","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2002-06-1793","article-title":"Radioimmunotherapy of non-Hodgkin lymphomas","volume":"101","author":"Cheson","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.06.008_bib51","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/sj.bmt.1705182","article-title":"Radioimmunoconjugates in acute leukemia treatment: the future is radiant","volume":"36","author":"Kotzerke","year":"2005","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.beha.2006.06.008_bib52","first-page":"4471a","article-title":"Intensification of the conditioning regimen for high-risk leukaemia with a 188Re- labelled anti-CD 164b monoclonal antibody: results of feasibility study","volume":"92","author":"Bunjes","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.06.008_bib53","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1182\/blood.V98.3.565","article-title":"Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study","volume":"98","author":"Bunjes","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.06.008_bib54","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1182\/blood.V99.6.2270","article-title":"Transplantation-related toxicity and acute intestinal graft-versus-host disease after conditioning regimens intensified with Rhenium 188- labeled anti-CD66 monoclonal antibodies","volume":"99","author":"Klein","year":"2002","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692606000442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692606000442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T11:30:46Z","timestamp":1707219046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692606000442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["S1521692606000442"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2006.06.008","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}